Iovance’s AMTAGVI Gets. FDA Accelerated Approval for Advanced Melanoma
AMTAGVI is the first FDA-approved T cell therapy for a solid tumor cancer and first treatment option for advanced melanoma after anti-PD-1 and targeted therapy
AMTAGVI deploys patient-specific immune cells that recognize and fight cancer
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.